Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Generic Brand-Specified Prescriptions Not Permitting Substitution Decline to 15.9%: FY2015 Survey
The percentage of prescriptions that designated generics by brands and did not permit substitution to another brand fell to 15.9% in FY2015, down sharply from 44.8% in FY2014, according to the preliminary results of a survey reported at the Central…
To read the full story
Related Article
- MHLW Floats Incentive for Hospital-Pharmacy Collaboration to Reduce Drugs Prescribed to Elderly
November 10, 2015
- JMA Reps Express Opposition to Expansion of Divided Dispensing of Long-Term Prescriptions at Chuikyo
November 10, 2015
- MHLW Pitches Generic Incentive for In-Hospital Dispensing; Quality Worries Still Simmering at Chuikyo
November 9, 2015
- Chuikyo Wants to Stick to 14-Day Prescription Limit
November 9, 2015
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…